phloroglucinol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2153 108-73-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • phloroglucinol
  • phloroglucin
  • phloroglucine
  • 1,3,5-Benzenetriol
A trinitrobenzene derivative with antispasmodic properties that is used primarily as a laboratory reagent.
  • Molecular weight: 126.11
  • Formula: C6H6O3
  • CLOGP: 0.14
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 3
  • TPSA: 60.69
  • ALOGS: -0.55
  • ROTB: 0

Drug dosage:

None

ADMET properties:

None

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 113.39 36.50 44 2353 33792 63452833
Hepatocellular injury 107.58 36.50 40 2357 27341 63459284
Acute kidney injury 58.31 36.50 60 2337 263355 63223270
Cell death 55.58 36.50 14 2383 2587 63484038
Hyponatraemia 54.41 36.50 40 2357 111860 63374765
Cholestasis 54.07 36.50 25 2372 29409 63457216
Thrombocytopenia 45.82 36.50 41 2356 151116 63335509
Febrile bone marrow aplasia 41.26 36.50 14 2383 7311 63479314
Poisoning deliberate 38.98 36.50 15 2382 11203 63475422
Hepatosplenic candidiasis 38.72 36.50 7 2390 264 63486361

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperleukocytosis 65.57 30.53 16 1709 1986 34953220
Urethral valves 62.29 30.53 11 1714 275 34954931
Pancreatitis acute 60.74 30.53 29 1696 28112 34927094
Febrile bone marrow aplasia 47.01 30.53 17 1708 8192 34947014
Acute kidney injury 41.48 30.53 62 1663 304926 34650280
Puncture site haematoma 40.67 30.53 7 1718 150 34955056
Bicytopenia 39.07 30.53 11 1714 2373 34952833
Diarrhoea infectious 36.88 30.53 8 1717 589 34954617
Tuberculosis 35.46 30.53 14 1711 8563 34946643
Eosinophilia 30.76 30.53 18 1707 26204 34929002

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular injury 119.08 29.26 55 4037 47538 79692758
Drug reaction with eosinophilia and systemic symptoms 111.98 29.26 58 4034 64186 79676110
Acute kidney injury 91.36 29.26 122 3970 519282 79221014
Pancreatitis acute 84.15 29.26 44 4048 49560 79690736
Febrile bone marrow aplasia 77.35 29.26 28 4064 12992 79727304
Cholestasis 68.36 29.26 39 4053 52070 79688226
Hyperleukocytosis 65.51 29.26 17 4075 2593 79737703
Thrombocytopenia 55.36 29.26 68 4024 265191 79475105
Cell death 51.39 29.26 16 4076 4683 79735613
Toxic skin eruption 50.25 29.26 24 4068 22269 79718027
Eosinophilia 41.59 29.26 27 4065 45318 79694978
Abdominal pain 40.59 29.26 72 4020 389497 79350799
Puncture site haematoma 39.24 29.26 7 4085 178 79740118
Hypokalaemia 38.51 29.26 42 4050 143998 79596298
Drug ineffective 36.42 29.26 6 4086 1080907 78659389
Hyponatraemia 36.08 29.26 45 4047 177803 79562493
Hepatic cytolysis 34.72 29.26 20 4072 27131 79713165
Wrong product administered 34.23 29.26 14 4078 8998 79731298
Acute generalised exanthematous pustulosis 34.15 29.26 17 4075 17237 79723059
Neutropenia 33.63 29.26 56 4036 287654 79452642
Poisoning deliberate 32.75 29.26 17 4075 18811 79721485
Gamma-glutamyltransferase increased 32.55 29.26 25 4067 54655 79685641
Porphyria 32.01 29.26 6 4086 202 79740094
Fatigue 31.65 29.26 5 4087 929722 78810574
Bicytopenia 31.35 29.26 11 4081 4659 79735637
Hepatosplenic candidiasis 31.16 29.26 7 4085 581 79739715
Rash maculo-papular 29.84 29.26 24 4068 56054 79684242

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A03AX12 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Other drugs for functional gastrointestinal disorders
MeSH PA D007202 Indicators and Reagents
CHEBI has role CHEBI:84735 algal metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.35 acidic
pKa2 10.35 acidic
pKa3 12.36 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-secretase 1 Enzyme IC50 4.44 CHEMBL

External reference:

IDSource
N0000166595 NUI
D00152 KEGG_DRUG
C0031566 UMLSCUI
CHEBI:16204 CHEBI
13X PDB_CHEM_ID
CHEMBL473159 ChEMBL_ID
359 PUBCHEM_CID
DB12944 DRUGBANK_ID
D010696 MESH_DESCRIPTOR_UI
DHD7FFG6YS UNII
8196 RXNORM
005931 NDDF
19341000122103 SNOMEDCT_US

Pharmaceutical products:

None